ECSP034922A - PIRROLOPIRIMIDINES - Google Patents

PIRROLOPIRIMIDINES

Info

Publication number
ECSP034922A
ECSP034922A EC2003004922A ECSP034922A ECSP034922A EC SP034922 A ECSP034922 A EC SP034922A EC 2003004922 A EC2003004922 A EC 2003004922A EC SP034922 A ECSP034922 A EC SP034922A EC SP034922 A ECSP034922 A EC SP034922A
Authority
EC
Ecuador
Prior art keywords
compounds
bioisoesters
prodrugs
solvates
oxides
Prior art date
Application number
EC2003004922A
Other languages
Spanish (es)
Inventor
Michael Louis Edwards
David John Aldous
Paul Joseph Cox
Franck Halley
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Brian Leslie Pedgrift
Iain Mcfarlane Mclay
Christopher Edlin
Bernard Baudoin
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP034922A publication Critical patent/ECSP034922A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A N-óxidos, profármacos, bioisoésteres ácidos, sales farmacéuticamente aceptables o solvatos de tales compuestos, ó N-óxidos, profármacos, ó bioisoésteres ácidos de tales sales ó solvatos; a composiciones que comprenden tales compuestos; y a métodos de tratamiento que comprenden administrar, a un paciente que lo necesite, tales compuestos y composicionesA N-oxides, prodrugs, acid bioisoesters, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisoesters of such salts or solvates; to compositions comprising such compounds; and to treatment methods comprising administering such compounds and compositions to a patient in need.

EC2003004922A 2001-06-23 2003-12-23 PIRROLOPIRIMIDINES ECSP034922A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
ECSP034922A true ECSP034922A (en) 2004-04-28

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004922A ECSP034922A (en) 2001-06-23 2003-12-23 PIRROLOPIRIMIDINES

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ES2445208T3 (en) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds for use in methods to treat or prevent autoimmune diseases
BRPI0413018B8 (en) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc compost, and use of a compost
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
JP2007512316A (en) * 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク Method for treating atherosclerosis
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
ATE479687T1 (en) 2004-10-15 2010-09-15 Takeda Pharmaceutical KINASE INHIBITORS
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
JP5748659B2 (en) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド New tricyclic compounds
JP5775070B2 (en) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d] pyrimidine and pyrrol-3-yl-pyrrolo [2,3-d] pyrimidine as Janus kinase inhibitors
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
PE20121336A1 (en) * 2009-12-01 2012-11-03 Abbvie Inc NEW TRICYCLIC COMPOUNDS
PT3354652T (en) 2010-03-10 2020-07-20 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
RS54824B1 (en) 2010-05-21 2016-10-31 Incyte Holdings Corp TOPICAL FORMULATION FOR JAK INHIBITION
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
RS55684B1 (en) 2012-07-26 2017-07-31 Glaxo Group Ltd 2- (AZAINDOL-2-IL) BENZIMIDAZOLES AS PAD4 INHIBITORS
MX2015002887A (en) * 2012-09-06 2015-07-06 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
CN113384546A (en) 2012-11-15 2021-09-14 因赛特公司 Sustained release dosage forms of ruxolitinib
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
TW201444820A (en) 2013-03-13 2014-12-01 Abbvie Inc Pyridine CDK9 kinase inhibitors
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
US9073922B2 (en) 2013-03-14 2015-07-07 Abbvie, Inc. Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
MX2015012899A (en) 2013-03-14 2016-06-02 Abbvie Inc Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors.
CA2903538A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120661512A (en) 2017-03-09 2025-09-19 艾伯维公司 Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
EA202091830A1 (en) 2018-01-30 2020-12-29 Инсайт Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR OBTAINING JAK INHIBITOR
MD3773593T2 (en) 2018-03-30 2024-10-31 Incyte Corp Treatment of hidradenitis suppurativa using JAK inhibitors
JP7640458B2 (en) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Compounds and compositions for treating conditions associated with APJ receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217873T1 (en) * 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
US6413971B1 (en) * 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
BR9911365A (en) * 1998-06-19 2001-03-13 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
CA2344262A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives

Also Published As

Publication number Publication date
NZ529766A (en) 2008-11-28
EA007415B1 (en) 2006-10-27
CZ20033443A3 (en) 2004-03-17
AU2002314325B8 (en) 2009-01-29
BR0210652A (en) 2004-08-10
WO2003000695A1 (en) 2003-01-03
SK15882003A3 (en) 2004-07-07
AU2002314325B2 (en) 2009-01-08
CN1518552A (en) 2004-08-04
MEP19308A (en) 2010-06-10
TNSN03144A1 (en) 2005-12-23
CN1294135C (en) 2007-01-10
JP2005508300A (en) 2005-03-31
UA76760C2 (en) 2006-09-15
RS99203A (en) 2006-12-15
EP1404676A1 (en) 2004-04-07
HUP0400300A3 (en) 2010-12-28
CA2451932C (en) 2009-12-29
CA2451932A1 (en) 2003-01-03
GB0115393D0 (en) 2001-08-15
RS51698B (en) 2011-10-31
OA12632A (en) 2006-06-14
TR200302242T2 (en) 2004-12-21
EE05432B1 (en) 2011-06-15
EE200400003A (en) 2004-02-16
PL374096A1 (en) 2005-09-19
WO2003000695A8 (en) 2004-03-11
EA200400073A1 (en) 2004-08-26
JP4344607B2 (en) 2009-10-14
HUP0400300A2 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
ECSP034922A (en) PIRROLOPIRIMIDINES
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
CR7193A (en) PIRROLOPIRIMIDINAS AS INHIBITORS OF THE KINASA PROTENINE
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
SE0001899D0 (en) New compounds
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
TW200510375A (en) New compounds
HUP0202570A1 (en) Compositions and therapeutic methods involving isoflavones and analogues thereof
EE05419B1 (en) Substituted oxazolidinones for combination therapy
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
GB0002336D0 (en) Medicaments
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
GB0130677D0 (en) Medicaments and novel compounds
MXPA04011835A (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent.
MY136386A (en) New combination of a betablocker and a cholesterol-lowering agent
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.
SE0004827D0 (en) Therapeutic compounds
BG105984A (en) Osanetant in the treatment of mood disorders
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents